Your browser doesn't support javascript.
loading
Discovery of a novel inhibitor of macropinocytosis with antiviral activity.
Porebski, Bartlomiej; Christ, Wanda; Corman, Alba; Haraldsson, Martin; Barz, Myriam; Lidemalm, Louise; Häggblad, Maria; Ilmain, Juliana; Wright, Shane C; Murga, Matilde; Schlegel, Jan; Jarvius, Malin; Lapins, Maris; Sezgin, Erdinc; Bhabha, Gira; Lauschke, Volker M; Carreras-Puigvert, Jordi; Lafarga, Miguel; Klingström, Jonas; Huhn, Daniela; Fernandez-Capetillo, Oscar.
Afiliación
  • Porebski B; Science for Life Laboratory, Division of Genome Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institute, S-171 21 Stockholm, Sweden.
  • Christ W; Center of Infectious Medicine, Department of Medicine, Karolinska Institutet, 141-86 Huddinge, Sweden.
  • Corman A; Science for Life Laboratory, Division of Genome Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institute, S-171 21 Stockholm, Sweden.
  • Haraldsson M; Chemical Biology Consortium Sweden, Science for Life Laboratory, Department of Medical Biochemistry and Biophysics, Karolinska Institute, SE-171 77 Stockholm, Sweden.
  • Barz M; Science for Life Laboratory, Division of Genome Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institute, S-171 21 Stockholm, Sweden.
  • Lidemalm L; Science for Life Laboratory, Division of Genome Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institute, S-171 21 Stockholm, Sweden.
  • Häggblad M; Science for Life Laboratory, Division of Genome Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institute, S-171 21 Stockholm, Sweden.
  • Ilmain J; Grossman School of Medicine, New York University, NY 10016, New York, United States of America.
  • Wright SC; Department of Physiology and Pharmacology, Karolinska Institute, S-171 77 Stockholm, Sweden.
  • Murga M; Genomic Instability Group, Spanish National Cancer Research Centre (CNIO), Madrid 28029, Spain.
  • Schlegel J; Science for Life Laboratory, Department of Women's and Children's Health, Karolinska Institutet, SE-171 77 Stockholm, Sweden.
  • Jarvius M; Department of Pharmaceutical Biosciences and Science for Life Laboratory, Uppsala University, Box 591, SE-751 24, Sweden; Chemical Biology Consortium Sweden, Science for Life Laboratory, Department of Pharmaceutical Biosciences, Uppsala University, Box 591, SE-751 24, Sweden.
  • Lapins M; Department of Pharmaceutical Biosciences and Science for Life Laboratory, Uppsala University, Box 591, SE-751 24, Sweden.
  • Sezgin E; Science for Life Laboratory, Department of Women's and Children's Health, Karolinska Institutet, SE-171 77 Stockholm, Sweden.
  • Bhabha G; Grossman School of Medicine, New York University, NY 10016, New York, United States of America.
  • Lauschke VM; Department of Physiology and Pharmacology, Karolinska Institute, S-171 77 Stockholm, Sweden; Margarete Fischer-Bosch Institute of Clinical Pharmacology, D-70376 Stuttgart, Germany; University of Tuebingen, 72074, Tuebingen, Germany.
  • Carreras-Puigvert J; Department of Pharmaceutical Biosciences and Science for Life Laboratory, Uppsala University, Box 591, SE-751 24, Sweden; Chemical Biology Consortium Sweden, Science for Life Laboratory, Department of Pharmaceutical Biosciences, Uppsala University, Box 591, SE-751 24, Sweden.
  • Lafarga M; Departament of Anatomy and Cellular Biology, Neurodegenerative diseases network (CIBERNED), University of Cantabria-IDIVAL, 39011, Santander, Spain.
  • Klingström J; Center of Infectious Medicine, Department of Medicine, Karolinska Institutet, 141-86 Huddinge, Sweden; Department of Biomedical and Clinical Sciences, Linköping University, 581 83, Linköping, Sweden.
  • Huhn D; Science for Life Laboratory, Division of Genome Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institute, S-171 21 Stockholm, Sweden.
  • Fernandez-Capetillo O; Science for Life Laboratory, Division of Genome Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institute, S-171 21 Stockholm, Sweden; Genomic Instability Group, Spanish National Cancer Research Centre (CNIO), Madrid 28029, Spain. Electronic address: oscar.fernandez-capetillo@
Mol Ther ; 2024 Jul 01.
Article en En | MEDLINE | ID: mdl-38956870
ABSTRACT
Several viruses hijack various forms of endocytosis in order to infect host cells. Here, we report the discovery of a molecule with antiviral properties that we named virapinib, which limits viral entry by macropinocytosis. The identification of virapinib derives from a chemical screen using High-Throughput Microscopy, where we identified chemical entities capable of preventing infection with a pseudotype virus expressing the spike (S) protein from SARS-CoV-2. Subsequent experiments confirmed the capacity of virapinib to inhibit infection by SARS-CoV-2, as well as by additional viruses, such as Monkeypox virus and TBEV. Mechanistic analyses revealed that the compound inhibited macropinocytosis, limiting this entry route for the viruses. Importantly, virapinib has no significant toxicity to host cells. In summary, we present the discovery of a molecule that inhibits macropinocytosis, thereby limiting the infectivity of viruses that use this entry route such as SARS-CoV2.

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: Mol Ther Asunto de la revista: BIOLOGIA MOLECULAR / TERAPEUTICA Año: 2024 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: Mol Ther Asunto de la revista: BIOLOGIA MOLECULAR / TERAPEUTICA Año: 2024 Tipo del documento: Article